Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants
暂无分享,去创建一个
Carla Oliveira | Rachid Karam | Chimene Kesserwan | Leora Witkowski | Tina Pesaran | David Huntsman | Fatima Carneiro | Joana Figueiredo | Kristy Lee | A. Spurdle | D. Huntsman | Kristy Lee | S. Plon | T. Slavin | R. Ghosh | C. Kesserwan | Liying Zhang | T. Pesaran | E. Chao | K. Dixon | K. Schrader | Carla Oliveira | R. Karam | F. Carneiro | A. Mensenkamp | Liying Zhang | Amanda B Spurdle | Michael J. Anderson | L. Witkowski | P. Kaurah | Elizabeth Chao | Shuwei Li | Kate Krempely | M. Roberts | J. Figueiredo | Tyler A. Landrith | C. Pardo | M. Richardson | Mackenzie Trapp | Charles S Yi | Rajarshi Ghosh | Sharon E Plon | Kasmintan A Schrader | Arjen R Mensenkamp | Michael J Anderson | Shuwei Li | Kate Krempely | Katherine Dixon | Maegan E Roberts | Pardeep Kaurah | Tyler Landrith | Carolina Pardo | Matthew Richardson | Thomas P Slavin | Mackenzie Trapp | Charles S. Yi
[1] L. Biesecker,et al. The ACMG/AMP reputable source criteria for the interpretation of sequence variants , 2018, Genetics in Medicine.
[2] R. Karam,et al. A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense-mediated mRNA decay , 2018, Cold Spring Harbor molecular case studies.
[3] Sara B. Willett,et al. DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes , 2018, Genetics in Medicine.
[4] Sitao Wu,et al. Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay , 2018, Front. Oncol..
[5] B. Bonanni,et al. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect , 2018, Journal of Medical Genetics.
[6] Bruce D. Gelb,et al. ClinGen’s RASopathy Expert Panel Consensus Methods for Variant Interpretation , 2018, Genetics in Medicine.
[7] P. Derksen,et al. Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer. , 2018, Cold Spring Harbor Perspectives in Biology.
[8] Birgit Funke,et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.
[9] Ruifeng Lu,et al. A central role for cadherin signaling in cancer. , 2017, Experimental cell research.
[10] Y. Saeys,et al. Evolution and diversity of cadherins and catenins. , 2017, Experimental cell research.
[11] Julie O. Culver,et al. Unexpected CDH1 Mutations Identified on Multigene Panels Pose Clinical Management Challenges. , 2017, JCO precision oncology.
[12] C. Boland,et al. Historical Perspective on Familial Gastric Cancer , 2017, Cellular and molecular gastroenterology and hepatology.
[13] Soma Das,et al. Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.
[14] D. MacArthur,et al. Using high-resolution variant frequencies to empower clinical genome interpretation , 2016, Genetics in Medicine.
[15] Laura H. Tang,et al. CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5’ Splice Site , 2016, PloS one.
[16] Madhuri Hegde,et al. Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine. , 2016, American journal of human genetics.
[17] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[18] R. Sijmons,et al. ClinGen and Genetic Testing. , 2015, The New England journal of medicine.
[19] A. Wagner,et al. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. , 2015, Gastroenterology.
[20] J. Adams. HIV Outbreak in Indiana. , 2015, New England Journal of Medicine.
[21] Heidi L Rehm,et al. ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.
[22] R. van Hillegersberg,et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers , 2015, Journal of Medical Genetics.
[23] Emily K. Tsang,et al. Effect of predicted protein-truncating genetic variants on the human transcriptome , 2015, Science.
[24] B. Fernandez,et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. , 2015, JAMA oncology.
[25] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[26] R. Seruca,et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. , 2015, The Lancet. Oncology.
[27] T. Pesaran,et al. ClinGen and Genetic Testing. , 2015, The New England journal of medicine.
[28] R. Seruca,et al. Hereditary diffuse gastric cancer - pathophysiology and clinical management. , 2014, Best practice & research. Clinical gastroenterology.
[29] Tina Pesaran,et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.
[30] H. Sugimura,et al. Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene , 2013, Gastric Cancer.
[31] F. Roviello,et al. E-cadherin germline missense mutations in diffuse gastric cancer , 2013 .
[32] M. Shah,et al. Gastric cancer epidemiology and risk factors , 2013, Journal of surgical oncology.
[33] M. Ligtenberg,et al. Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC) , 2013, European Journal of Human Genetics.
[34] R. Seruca,et al. The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC , 2012, European Journal of Human Genetics.
[35] M. Shah,et al. De novo CDH1 mutation in a family presenting with early‐onset diffuse gastric cancer , 2012, Clinical genetics.
[36] L. Serrano,et al. E-Cadherin Destabilization Accounts for the Pathogenicity of Missense Mutations in Hereditary Diffuse Gastric Cancer , 2012, PloS one.
[37] R. Seruca,et al. Hereditary gastric cancer. , 2009, Best practice & research. Clinical gastroenterology.
[38] F. van Roy,et al. Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. , 2008, Human molecular genetics.
[39] A. Spurdle,et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.
[40] D. Huntsman,et al. The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers , 2008, Oncogene.
[41] B. Fernandez,et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.
[42] R. Seruca,et al. A model to infer the pathogenic significance of CDH1 germline missense variants , 2006, Journal of Molecular Medicine.
[43] M. Inoue,et al. Epidemiology of gastric cancer in Japan , 2005, Postgraduate Medical Journal.
[44] M Vekemans,et al. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer , 2005, Journal of Medical Genetics.
[45] M. Hentze,et al. Nonsense-mediated decay approaches the clinic , 2004, Nature Genetics.
[46] C. Caldas,et al. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer , 2004, Gut.
[47] D. Huntsman,et al. E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. , 2003, Human molecular genetics.
[48] J. Yokota,et al. The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell–cell adhesion and to suppress invasion , 2003, Oncogene.
[49] B. Anderson,et al. Trends in incidence rates of invasive lobular and ductal breast carcinoma. , 2003, JAMA.
[50] Carla Oliveira,et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. , 2003, Human molecular genetics.
[51] D. Longo,et al. Truncation of the extracellular region abrogrates cell contact but retains the growth-suppressive activity of E-cadherin. , 2000, Cancer research.
[52] H. Höfler,et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. , 1999, The American journal of pathology.
[53] Anthony E. Reeve,et al. E-cadherin germline mutations in familial gastric cancer , 1998, Nature.
[54] M. Vijver,et al. E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.
[55] D. Riethmacher,et al. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Takeichi,et al. Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.